OTC - ACTIVE INGREDIENT SECTION
OCTINOXATE 7%
TITANIUM DIOXIDE 6.72%
ZINC OXIDE 2.88%
HYDROXYPROLINE 0.5 %
ATRACTYLODES JAPONICA ROOT OIL 0.05%
OCTINOXATE 7%
TITANIUM DIOXIDE 6.72%
ZINC OXIDE 2.88%
HYDROXYPROLINE 0.5 %
ATRACTYLODES JAPONICA ROOT OIL 0.05%
For external use only.
Keep out of reach of children. Is swallowed, get medical help or contact a Poison Control Center right away.
Keep out of eyes. Rinse with water to remove.
Stop use if a rash or irritation develops and lasts.
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 77dc03a4-fbfc-e6a3-fe95-285bbae40d75 | Product name | 2 | 20250814 |
| a21a21e5-f36d-4c1f-8918-def921b8f7e3 | Product name | 3 | 20250124 |
| 910c1bd7-67d1-44c7-ad4f-9445f827edcc | Product name | 1 | 20230808 |
| 6bd95106-a412-1dad-b9cc-4cb74bfb27ce | Product name | 2 | 20230315 |
| d5e51f11-ad28-caa4-4b49-4143974782ad | Product name | 1 | 20150831 |
| 290f523a-f9db-9774-b5a9-e1f908ac1782 | Product name | 1 | 20150828 |
| 0ca1d589-929b-4b33-bc5b-1d84abdafa6a | Product name | 1 | 20150324 |
| fc363c46-397b-4476-ac0f-70e43e8e4592 | Product name | 1 | 20150324 |
| c6b65c52-69c7-df49-550a-a50c137f6218 | Product name | 1 | 20140508 |
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 53208-520-02 | 2019-10-29 | C162847 | 48780-1 | 960f7f55-cd9d-8e05-e053-dbdaa90a074a | Drug Facts |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 53208-520-01 | ISA KNOX SMART BB SUN | 60 mL in 1 CONTAINER | CREAM | 60 | 1 | |
| 53208-520-02 | ISA KNOX SMART BB SUN | 1 in 1 BOX | CREAM | 1 | 1 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 53208-520 | ISA KNOX SMART BB SUN (OCTINOXATE, TITANIUM DIOXIDE, ZINC OXIDE, HYDROXYPROLINE, ATRACTYLODES JAPONICA ROOT OIL) CREAM [LG HOUSEHOLD AND HEALTHCARE, INC.] | 1 | Legacy NDC, 2 package rows | 20110415_3b4ab30b-920a-4790-8f3b-8c744f2f6a57.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| ATRACTYLODES JAPONICA ROOT OIL | ACTIVE INGREDIENT | EC228KGY00 | 1 | |
| HYDROXYPROLINE | ACTIVE INGREDIENT | RMB44WO89X | 1 | |
| OCTINOXATE | ACTIVE INGREDIENT | 4Y5P7MUD51 | 1 | |
| TITANIUM DIOXIDE | ACTIVE INGREDIENT | 15FIX9V2JP | 1 | |
| ZINC OXIDE | ACTIVE INGREDIENT | SOI2LOH54Z | 1 | |
| ATRACTYLODES JAPONICA ROOT OIL | ACTIVE MOIETY | EC228KGY00 | 1 | |
| HYDROXYPROLINE | ACTIVE MOIETY | RMB44WO89X | 1 | |
| OCTINOXATE | ACTIVE MOIETY | 4Y5P7MUD51 | 1 | |
| TITANIUM DIOXIDE | ACTIVE MOIETY | 15FIX9V2JP | 1 | |
| ZINC OXIDE | ACTIVE MOIETY | SOI2LOH54Z | 1 | |
| ACETATE ION | INACTIVE INGREDIENT | 569DQM74SC | 1 | |
| BUTYLENE GLYCOL | INACTIVE INGREDIENT | 3XUS85K0RA | 1 | |
| CANNA INDICA ROOT | INACTIVE INGREDIENT | BZK836AQFQ | 1 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 1 | |
| DISTEARYLDIMONIUM CHLORIDE | INACTIVE INGREDIENT | OM9573ZX3X | 1 | |
| ENSULIZOLE | INACTIVE INGREDIENT | 9YQ9DI1W42 | 1 | |
| FERRIC OXIDE RED | INACTIVE INGREDIENT | 1K09F3G675 | 1 | |
| FERROSOFERRIC OXIDE | INACTIVE INGREDIENT | XM0M87F357 | 1 | |
| HECTORITE | INACTIVE INGREDIENT | 08X4KI73EZ | 1 | |
| IRON | INACTIVE INGREDIENT | E1UOL152H7 | 1 | |
| MAGNESIUM SULFATE, UNSPECIFIED | INACTIVE INGREDIENT | DE08037SAB | 1 | |
| MARITIME PINE | INACTIVE INGREDIENT | 50JZ5Z98QY | 1 | |
| METHYL TRIMETHICONE | INACTIVE INGREDIENT | S73ZQI0GXM | 1 | |
| METHYLPARABEN | INACTIVE INGREDIENT | A2I8C7HI9T | 1 | |
| PANTHENOL | INACTIVE INGREDIENT | WV9CM0O67Z | 1 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 1 | |
| PROPYLPARABEN | INACTIVE INGREDIENT | Z8IX2SC1OH | 1 | |
| SACCHARIDE ISOMERATE | INACTIVE INGREDIENT | W8K377W98I | 1 | |
| STEARIC ACID | INACTIVE INGREDIENT | 4ELV7Z65AP | 1 | |
| TRISILOXANE | INACTIVE INGREDIENT | 9G1ZW13R0G | 1 | |
| TROMETHAMINE | INACTIVE INGREDIENT | 023C2WHX2V | 1 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 53208-520 | 53208-520-01, 53208-520-02 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CONCENTRATE / ORAL | 12 mg | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SUSPENSION / INTRATYMPANIC | 2 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, DELAYED RELEASE / ORAL | 37 mg | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | INJECTION, SOLUTION / INTRAVASCULAR | 225 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, DELAYED RELEASE / ORAL | 80 mg | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | INJECTION, SOLUTION / INTRAMUSCULAR | 1.21 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | ENEMA / RECTAL | 0.18 %w/v | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | GEL / TOPICAL | 56 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | TABLET, EXTENDED RELEASE / ORAL | 0.12 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / ORAL | 64 mg | ||
| MAGNESIUM SULFATE, UNSPECIFIED | MAGNESIUM SULFATE | DE08037SAB | SOAP / TOPICAL | 0.2 %w/w | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | ENEMA / RECTAL | 0.02 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INTRALESIONAL | 0.15 %w/v | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | GEL / TRANSDERMAL | 10 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / TOPICAL | 24 mg | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | POWDER, FOR SUSPENSION / ORAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | DROPS / ORAL | 1 mg/1ml | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION / OPHTHALMIC | 0.75 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SPRAY / TOPICAL | 0.8 %w/w | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | INJECTION, SOLUTION / INTRAVENOUS | 300 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, COATED / ORAL | 0.12 mg | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | TABLET, EXTENDED RELEASE / ORAL | 8 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | JELLY / TOPICAL | 420 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | LOTION / TOPICAL | 140 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | TABLET, CHEWABLE / ORAL | 0.14 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / IONTOPHORESIS | 0.1 %w/v | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, DELAYED RELEASE / ORAL | 14 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | IMPLANT / SUBCUTANEOUS | 1.04 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / NASAL | 250 mg | ||
| MAGNESIUM SULFATE, UNSPECIFIED | MAGNESIUM SULFATE | DE08037SAB | TABLET, EXTENDED RELEASE / ORAL | 4 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | SOAP / TOPICAL | 6 %w/w | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | PELLET / SUBCUTANEOUS | 0.97 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | GEL / TOPICAL | 4 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | DROPS / AURICULAR (OTIC) | NA | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | INJECTION, SOLUTION / INTRA-ARTERIAL | 300 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CREAM, AUGMENTED / TOPICAL | 2 mg | ||
| BUTYLENE GLYCOL | BUTYLENE GLYCOL | 3XUS85K0RA | SYSTEM / TRANSDERMAL | 8.12 mg | ||
| MAGNESIUM SULFATE, UNSPECIFIED | MAGNESIUM SULFATE | DE08037SAB | TABLET, COATED / ORAL | NA | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION, GEL FORMING / DROPS / OPHTHALMIC | 1 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION, EXTENDED RELEASE / ORAL | 4 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / OPHTHALMIC | 0.05 %w/w | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CAPSULE / ORAL | 7 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | ELIXIR / ORAL | 800 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SOLUTION / ORAL | 100 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CREAM / TOPICAL | 6 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUSPENSION / AURICULAR (OTIC) | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / SUBCUTANEOUS | 22 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION, POWDER, FOR SOLUTION / INTRAMUSCULAR | 3.6 mg | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION / RECTAL | 0.12 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | INJECTION, SUSPENSION / INTRAMUSCULAR | 0.02 %w/v | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | CREAM / VAGINAL | 22 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET / SUBLINGUAL | 9 mg | ||
| FERROSOFERRIC OXIDE | FERROSOFERRIC OXIDE | XM0M87F357 | CAPSULE / ORAL | 11 mg | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | INJECTION / INTRAMUSCULAR | 95 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | CREAM / VAGINAL | 3 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, COATED / ORAL | 42.4 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | JELLY / NASAL | 140 mg | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | SUPPOSITORY / VAGINAL | NA | ||
| METHYLPARABEN | METHYLPARABEN | A2I8C7HI9T | SOLUTION / INTRAVENOUS | 0.13 %w/v | ||
| PROPYLPARABEN | PROPYLPARABEN | Z8IX2SC1OH | OINTMENT / TOPICAL | 0.2 %w/w |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 216c9add-5ee7-494d-b2d2-00bf91e66cc5 | 3b4ab30b-920a-4790-8f3b-8c744f2f6a57 | 2011-04-12 | Warnings | 216c9add-5ee7-494d-b2d2-00bf91e66cc5 3b4ab30b-920a-4790-8f3b-8c744f2f6a57 |
Adverse event summaries are temporarily unavailable. Other product information remains available.